Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions

Dr. Robert M. Califf recently ended his second tenure as the Commissioner of the Food and Drug Administration (FDA). Our conversation occurred on his 1-month anniversary of becoming a private citizen again. In our conversation, Dr. Califf shares his perspective on pressing healthcare challenges following his second tenure as FDA Commissioner. Dr. Califf discusses the balancing act between accelerated drug approvals and evidence generation, emphasizing the need for robust postmarket studies and the health system's role in evidence generation. He also advocates for a fundamental shift toward prevention-focused, community-based healthcare supported by technology to address the paradox of spending and health outcomes in the United States. As healthcare leadership in the new administration shifts health priorities, Dr. Califf highlights critical vulnerabilities in pharmaceutical supply chains and the urgent need to combat health misinformation in the digital age.

Authors

Institutions

Publication Details

Journal
Health Affairs Scholar
Published
2025-04-12
DOI
https://doi.org/10.1093/haschl/qxaf075
Citations
1
Primary Topic
Primary Care and Health Outcomes
Type
article
Field-Weighted Citation Impact
2.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions

Danea Horn, Robert M. Califf, Kathryn A. Phillips
1 citations
Health Affairs Scholar
Primary Care and Health Outcomes
2.82
article

Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions

Danea Horn, Robert M. Califf, Kathryn A. Phillips
article en
1 citations

Abstract

Dr. Robert M. Califf recently ended his second tenure as the Commissioner of the Food and Drug Administration (FDA). Our conversation occurred on his 1-month anniversary of becoming a private citizen again. In our conversation, Dr. Califf shares his perspective on pressing healthcare challenges following his second tenure as FDA Commissioner. Dr. Califf discusses the balancing act between accelerated drug approvals and evidence generation, emphasizing the need for robust postmarket studies and the health system's role in evidence generation. He also advocates for a fundamental shift toward prevention-focused, community-based healthcare supported by technology to address the paradox of spending and health outcomes in the United States. As healthcare leadership in the new administration shifts health priorities, Dr. Califf highlights critical vulnerabilities in pharmaceutical supply chains and the urgent need to combat health misinformation in the digital age.

Health Affairs ScholarVol. 3(5)
United States Food and Drug Administration (US), University of California, San Francisco (US)
Openalex Percentile: Top 12%
Primary Care and Health Outcomes
2.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Beyond regulation: a conversation with Dr. Robert Califf on the challenges facing healthcare and innovating community-based solutions — Danea Horn, Robert M. Califf, et al. · Health Affairs Scholar (2025) | TGRS Research Map | TGRS